Literature DB >> 2754649

Relationship between heparin binding characteristics and ability of human spermatozoa to penetrate hamster ova.

R A Lalich1, S Vedantham, N McCormick, C Wagner, G S Prins.   

Abstract

Heparin binding site affinity and density on human spermatozoa were compared between fertile and infertile men with normal or abnormal results in the zona-free hamster ova-sperm penetration assay (SPA). A portion of fresh semen from fertile donors and potentially infertile men was processed through the SPA while the remainder of the ejaculate was used to quantitate heparin binding on spermatozoa. Saturation binding assays with [3H]heparin (15-375 nM) were analysed for 3 groups of men: (1) infertile patients with abnormal SPA results, (2) infertile patients with normal SPA results and (3) fertile donors. The heparin binding site density was significantly higher in men who possessed normal SPA results (infertile men and fertile donors) than in infertile men with abnormal scores in the SPA. There was no difference in heparin binding affinity between the three groups. These findings suggest that the heparin binding-site density may be related to the ability of human spermatozoa to undergo successfully the acrosome reaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754649     DOI: 10.1530/jrf.0.0860297

Source DB:  PubMed          Journal:  J Reprod Fertil        ISSN: 0022-4251


  2 in total

1.  Relationship between nuclear chromatin decondensation (NCD) in vitro and other sperm parameters and their predictive value on fertilization rate in IVF program.

Authors:  Mohamed E Hammadeh; Alexandra Bernardi; Theodosia Zeginiadou; Ahmed Amer; Werner Schmidt
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

2.  Rat recombinant β-defensin 22 is a heparin-binding protein with antimicrobial activity.

Authors:  Hua Diao; He-Guo Yu; Fei Sun; Yong-Lian Zhang; Nongnuj Tanphaichitr
Journal:  Asian J Androl       Date:  2010-12-13       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.